Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Inventiva S.A
IVA | US
2.73
USD0.10
3.80%
IVA | US
About Inventiva S.A
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/03/2024
As of date
21/10/2024
Close
2.73
Open
2.71
High
2.78
Low
2.69
Inventiva S.A. a clinical-stage biopharmaceutical company focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix France.
View LessIVA | US
Risk
178.2
Sharpe
-0.40
Luna's Score
39/100
Recommendation
Sell
Luna says (IVA | US)
What's Working
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
216.9%1 month
178.2%3 months
105.5%6 months
88.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.10
Debt to equity
-1.15
Debt to assets
0.54
Ent. to EBITDA
-1.34
Ent. to rev.
5.65
PEG
-
Other Fundamentals
EBITDA
-98.36M
MarketCap
144.01M
MarketCap(USD)
144.01M
Div. yield
-
Op. margin
-1.91K
Erngs. growth
-
Rev. growth
-58.70
Ret. on equity
-1.64K
Short ratio
14.15
Short perc.
0.46
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.25
Range1M
1.32
Range3M
1.32
Volumes: Market Activity
Rel. volume
0.23
Price X volume
396.91K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.34 | 0.53 | Cheaper |
| Ent. to Revenue | 5.65 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.10 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 105.53 | 72.80 | Riskier |
| Debt to Equity | -1.15 | -1.23 | Cheaper |
| Debt to Assets | 0.54 | 0.25 | Expensive |
| Market Cap | 144.01M | 3.66B | Emerging |
